Featured,Spotlight Stock,Trends & Articles Revive Therapeutics Completes Research on Oral Thin Film Psilocybin By Dennis Mutua April 23, 2021 Life sciences company specializing on research and development of therapies for infectious diseases and rare disorders Revive Therapeutics Ltd (CNSX: RVV) announced successful completion of its research on oral thin film (OTF) del...
Featured,Spotlight Stock,Trends & Articles Proprietary Mushrooms Shows Efficacy in Killing Breast Cancer Cells Says Aion Therapeutics By Dennis Mutua April 22, 2021 Life Sciences Company concentrating on research and production of medical cannabis and psychedelics therapies Aion Therapeutics Inc. (CNSX: AION) announced its proprietary and patented combinatorial mushroom preparations AION F7 a...
Featured,Spotlight Stock,Trends & Articles PharmaTher Submits Phase 2 Clinical Trials Application for Using Ketamine to Treat Parkison’s Disease By Dennis Mutua April 21, 2021 Life Sciences company focusing on research and development of psychedelic pharmaceuticals PharmaTher Holding Ltd. (CSE: PHRM) (OTCQB: PHRRF) announced having submitted an application to commence its phase 2 clinical trials to asse...
Featured,Shroom News,Spotlight Stock Halucenex Signs Agreement With Sixth Wave to Progress Research of Hallucinogenic Mushrooms By Dennis Mutua April 20, 2021 Life sciences development company focusing on novel psychedelics compounds to treat mental illnesses Halucenex Life Sciences has signed a non-binding letter of agreement (LOI) of agreement with Sixth Wave, a leading nanotechnology...
Featured,Trends & Articles U.S Psychedelics Drug Market Expected to Reach $6.9 Billion by 2027 By Dennis Mutua April 20, 2021 A business intelligent report released on 19 April by Department for BioMedical Research (DBMR) suggests that the psychedelics drug market in the United States will be worth over $6.85 billion by the year 2027. This projection ...
Featured,Trends & Articles Therapeutic Goods Administration Reconsidering Making Psilocybin Easily Accessible to Psychiatrist for Treatment of Mental Health By Dennis Mutua April 19, 2021 Australian medicine and therapeutic regulatory authority Therapeutic Goods Administration (TGA) acknowledged having received an application to make accessibility of MDAM and magic mushrooms easier for psychiatrists so as to help i...
Featured,Spotlight Stock,Trends & Articles UK Study Rules Magic Mushroom Compound Effective as Any Antidepressant Drugs By Dennis Mutua April 16, 2021 A study done by scientists from the UK has concluded that compound form magic mushroom is at least as good as antidepressant drugs. The study found out that the compound from magic mushroom is equally effective as any antidepressa...
Featured,Shroom News Psychedelics Bill Authorized by Senator Scott Weiner Passed by Senate Health Committee By Dennis Mutua April 15, 2021 United States Senate Health Committee passed a bill aimed at decimalizing use of psychedelics drugs authorized by the Senator of San Francisco Scott Weiner. The committee voted 6:1 in favor of the psychedelics bill. Senator Wei...